S100A4 inhibitor “Minnetamide” for prostate cancer treatment
Technology No. 2020-242
IP Status: Provisional Patent Application Filed; Application #: 63/037,355 Mohammad Saleem Bhat, PhD
Desired Partnerships
Application
- Prostate cancer treatment
Technology Overview
Current treatments for prostate cancers (PC) are highly variable in their efficacy, particularly in the case of aggressive forms of cancers such as neuroendocrine type PC (NEPC). The technology is a small molecule (called “S100A-Minnetamide”) that inhibits a novel drug target, S100 calcium-binding protein A4 (S100A4). In animal models of disease, S100A-Minnetamide is well tolerated, bioavailable and results in reduced cancer growth
Phase of Development
In vitro and in vivo/animal studies completed.
ResearchersAssociate Professor, Dept. of Urology
External Link (www.cancer.umn.edu)
Publications
- ”S100A4 accelerates tumorigenesis and invasion of human prostate cancer through the transcriptional regulation of matrix metalloproteinase 9.” PNAS, 2006.
- ”The S100A4 Oncoprotein Promotes Prostate Tumorigenesis in a Transgenic Mouse Model: Regulating NFκB through the RAGE Receptor.” Genes and Cancer, 2013.
Desired Partnerships
This technology is now available for:
- License
- Sponsored research
- Co-development